Australia-based Endo Axiom Pty Ltd has dosed its first human participants with an oral nanoparticle-encapsulated insulin formulation, marking the company's... London-based neurotechnology company ...
Endo Axiom begins first human dosing of oral insulin nanoparticles for type 1 diabetes. Phase Ia trial shows breakthrough in ...
Johns Hopkins receives $2.5 million NIH grant to study TLR4's role in necrotizing enterocolitis. Discover breakthrough ...
NeuroHarmonics begins first patient trial of non-invasive deep-brain ultrasound for essential tremor. MHRA cleared. Learn ...
IMUNON partners with National Cancer Institute to advance IMNN-001 IL-12 immunotherapy beyond ovarian cancer. NCI assumes ...
Navion Neurosciences secures $10.8M seed funding for precision sodium-channel medicines targeting genetic epilepsy and ...
Teva Pharmaceutical refinances $4.9B debt, retiring high-coupon notes up to 8.125%. Learn how the pharma giant extends its maturity profile and ...
Swedish Orphan Biovitrum receives FDA Fast Track Designation for pacritinib (Vonjo) treating VEXAS syndrome. Learn what this ...
Ethris GmbH secures €30M EIB financing for broad-spectrum nasal antiviral trials. mRNA respiratory treatment advances to ...
Yarrow Bioscience secures $150M funding to advance first-in-class Graves' disease antibody into Phase II trials. Latest ...
Third Arc Bio selects lead candidate for masked CD3 T cell engager under expanded Adagene collaboration. Milestone payments ...
FDA pushes zanzalintinib decision to March 2027. Exelixis' colorectal cancer drug review extended by 3 months. Latest updates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results